Literature DB >> 24935961

Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice.

Anna C Calkin1, Stephen D Lee1, Jason Kim1, Caroline M W Van Stijn1, Xiao-Hui Wu1, Aldons J Lusis1, Cynthia Hong1, Rajendra I Tangirala1, Peter Tontonoz2.   

Abstract

RATIONALE: The E3 ubiquitin ligase inducible degrader of the low-density lipoprotein receptor (IDOL) triggers lysosomal degradation of the low-density lipoprotein receptor. The tissue-specific effects of the IDOL pathway on plasma cholesterol and atherosclerosis have not been examined.
OBJECTIVE: Given that the liver is the primary determinant of plasma cholesterol levels, we sought to examine the consequence of effect of chronic liver-specific expression of a dominant-active form of IDOL in mice. METHODS AND
RESULTS: We expressed a degradation-resistant, dominant-active form of IDOL (super IDOL [sIDOL]) in C57Bl/6J mice from the liver-specific albumin promoter (L-sIDOL transgenics). L-sIDOL mice were fed a Western diet for 20 or 30 weeks and then analyzed for plasma lipid levels and atherosclerotic lesion formation. L-sIDOL mice showed dramatic reductions in hepatic low-density lipoprotein receptor protein and increased plasma low-density lipoprotein cholesterol levels on both chow and Western diets. Moreover, L-sIDOL mice developed marked atherosclerotic lesions when fed a Western diet. Lesion formation in L-sIDOL mice was more robust than in apolipoprotein E*3 Leiden mice and did not require the addition of cholate to the diet. Western diet-fed L-sIDOL mice had elevated expression of liver X receptor target genes and proinflammatory genes in their aortas.
CONCLUSIONS: Liver-specific expression of dominant-active IDOL is associated with hypercholesterolemia and a marked elevation in atherosclerotic lesions. Our results show that increased activity of the IDOL pathway in the liver can override other low-density lipoprotein receptor regulatory pathways leading to cardiovascular disease. L-sIDOL mice are a robust, dominantly inherited, diet-inducible model for the study of atherosclerosis.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  atherosclerosis; cholesterol, LDL; ubiquitin-protein ligases

Mesh:

Substances:

Year:  2014        PMID: 24935961      PMCID: PMC4119488          DOI: 10.1161/CIRCRESAHA.115.304440

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  26 in total

1.  Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice.

Authors:  R K Tangirala; E M Rubin; W Palinski
Journal:  J Lipid Res       Date:  1995-11       Impact factor: 5.922

2.  Synthetic LXR ligand inhibits the development of atherosclerosis in mice.

Authors:  Sean B Joseph; Elaine McKilligin; Liming Pei; Michael A Watson; Alan R Collins; Bryan A Laffitte; Mingyi Chen; Grace Noh; Joanne Goodman; Graham N Hagger; Jonathan Tran; Tim K Tippin; Xuping Wang; Aldons J Lusis; Willa A Hsueh; Ronald E Law; Jon L Collins; Timothy M Willson; Peter Tontonoz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans.

Authors:  Daphna Weissglas-Volkov; Anna C Calkin; Teresa Tusie-Luna; Janet S Sinsheimer; Noam Zelcer; Laura Riba; Ana Maria Vargas Tino; Maria Luisa Ordoñez-Sánchez; Ivette Cruz-Bautista; Carlos A Aguilar-Salinas; Peter Tontonoz; Päivi Pajukanta
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

4.  FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors.

Authors:  Anna C Calkin; Benjamin T Goult; Li Zhang; Louise Fairall; Cynthia Hong; John W R Schwabe; Peter Tontonoz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-22       Impact factor: 11.205

5.  Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential.

Authors:  Richard G Lee; Kathryn L Kelley; Janet K Sawyer; Robert V Farese; John S Parks; Lawrence L Rudel
Journal:  Circ Res       Date:  2004-10-14       Impact factor: 17.367

6.  Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein.

Authors:  Vincenzo Sorrentino; Sigrid W Fouchier; Mohammad M Motazacker; Jessica K Nelson; Joep C Defesche; Geesje M Dallinga-Thie; John J P Kastelein; G Kees Hovingh; Noam Zelcer
Journal:  Eur Heart J       Date:  2013-01-16       Impact factor: 29.983

7.  Variation in susceptibility to atherosclerosis among inbred strains of mice.

Authors:  B Paigen; A Morrow; C Brandon; D Mitchell; P Holmes
Journal:  Atherosclerosis       Date:  1985-10       Impact factor: 5.162

8.  Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice.

Authors:  Marion A M den Boer; Marit Westerterp; Jitske de Vries-van der Weij; Yanan Wang; Lihui Hu; Sonia M S Espirito Santo; Teake Kooistra; Peter Reiss; Johannes A Romijn; Louis M Havekes; Patrick C N Rensen
Journal:  Atherosclerosis       Date:  2009-12-01       Impact factor: 5.162

9.  Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.

Authors:  Cédric Le May; Jean Mathieu Berger; Anne Lespine; Bruno Pillot; Xavier Prieur; Eric Letessier; M Mahmood Hussain; Xavier Collet; Bertrand Cariou; Philippe Costet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-04       Impact factor: 8.311

10.  Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis.

Authors:  Daniel I Chasman; Guillaume Paré; Samia Mora; Jemma C Hopewell; Gina Peloso; Robert Clarke; L Adrienne Cupples; Anders Hamsten; Sekar Kathiresan; Anders Mälarstig; José M Ordovas; Samuli Ripatti; Alex N Parker; Joseph P Miletich; Paul M Ridker
Journal:  PLoS Genet       Date:  2009-11-20       Impact factor: 5.917

View more
  9 in total

1.  The SCFFBXO3 ubiquitin E3 ligase regulates inflammation in atherosclerosis.

Authors:  Divay Chandra; James Londino; Shaun Alexander; Joseph S Bednash; Yingze Zhang; Robert M Friedlander; Grant Daskivich; Diane L Carlisle; William R Lariviere; Ana Carolina Igami Nakassa; Mark Ross; Claudette St Croix; Toru Nyunoya; Frank Sciurba; Bill Chen; Rama K Mallampalli
Journal:  J Mol Cell Cardiol       Date:  2018-11-16       Impact factor: 5.000

2.  Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia.

Authors:  Melody Lok-Yi Chan; Sammy Wing-Ming Shiu; Ching-Lung Cheung; Anskar Yu-Hung Leung; Kathryn Choon-Beng Tan
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

3.  IDOL regulates systemic energy balance through control of neuronal VLDLR expression.

Authors:  Stephen D Lee; Christina Priest; Mikael Bjursell; Jie Gao; Douglas V Arneson; In Sook Ahn; Graciel Diamante; J Edward van Veen; Megan G Massa; Anna C Calkin; Jason Kim; Harriet Andersén; Prashant Rajbhandari; Michelle Porritt; Alba Carreras; Andrea Ahnmark; Frank Seeliger; Ingela Maxvall; Pernilla Eliasson; Magnus Althage; Peter Åkerblad; Daniel Lindén; Tracy A Cole; Richard Lee; Helen Boyd; Mohammad Bohlooly-Y; Stephanie M Correa; Xia Yang; Peter Tontonoz; Cynthia Hong
Journal:  Nat Metab       Date:  2019-10-28

4.  Idol Depletion Protects against Spontaneous Atherosclerosis in a Hamster Model of Familial Hypercholesterolemia.

Authors:  Chenxi Liang; Xiaowei Wang; Kenan Peng; Pingping Lai; Ziwei Liu; Jiaao Ma; Xin Chen; Gang Liu; Mingqi Zheng; Yuhui Wang; Hongyuan Yang; George Liu; Xunde Xian; Mingming Gao
Journal:  Oxid Med Cell Longev       Date:  2022-05-24       Impact factor: 7.310

5.  A Novel Type 2 Diabetes Mouse Model of Combined Diabetic Kidney Disease and Atherosclerosis.

Authors:  Karin E Bornfeldt; Farah Kramer; Anna Batorsky; Jinkuk Choi; Kelly L Hudkins; Peter Tontonoz; Charles E Alpers; Jenny E Kanter
Journal:  Am J Pathol       Date:  2017-12-15       Impact factor: 4.307

6.  The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis.

Authors:  Jinkuk Choi; Jie Gao; Jaekwang Kim; Cynthia Hong; Jungsu Kim; Peter Tontonoz
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

Review 7.  Liver X receptors at the intersection of lipid metabolism and atherogenesis.

Authors:  Stephen D Lee; Peter Tontonoz
Journal:  Atherosclerosis       Date:  2015-07-02       Impact factor: 5.162

8.  IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population.

Authors:  Ashish Dhyani; Gianpaolo Tibolla; Andrea Baragetti; Katia Garlaschelli; Fabio Pellegatta; Liliana Grigore; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

9.  Endothelial NOTCH1 is suppressed by circulating lipids and antagonizes inflammation during atherosclerosis.

Authors:  Anaïs Briot; Mete Civelek; Atsuko Seki; Karen Hoi; Julia J Mack; Stephen D Lee; Jason Kim; Cynthia Hong; Jingjing Yu; Gregory A Fishbein; Ladan Vakili; Alan M Fogelman; Michael C Fishbein; Aldons J Lusis; Peter Tontonoz; Mohamad Navab; Judith A Berliner; M Luisa Iruela-Arispe
Journal:  J Exp Med       Date:  2015-11-09       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.